Literature DB >> 7952145

Pathogenesis of Sjögren's syndrome-like autoimmune lesions in MRL/lpr mice.

Y Hayashi1, N Haneji, H Hamano.   

Abstract

Sjögren's syndrome in humans is a chronic inflammatory disease with a presumed autoimmune etiology of the exocrine organs, involving in particular the salivary and lacrimal glands. The pathogenesis of this syndrome remains unclear, but the majority of infiltrating cells in the salivary glands are CD4+ T cells both in humans and rodents. Since many cytokines are involved in the development of T cell-mediated autoimmunity, local cytokine gene expression was analyzed in vivo using an animal model for Sjögren's syndrome in MRL/lpr mice. Overexpression of interleukin-1 (IL-1)beta and tumour necrosis factor (TNF) was detected before the onset of inflammatory lesions in the salivary gland, and the upregulation of IL-6 mRNA was also found in accordance with autoimmune sialadenitis in MRL/lpr mice. The inflammatory cytokines such as IL-1 beta, TNF, and IL-6 have proved to play important roles as regulatory proteins inducing autoimmune phenomena. In addition, the expression of T cell antigen receptor beta (TCR) beta transcripts in the salivary gland tissues was analyzed. Transcript for V beta 8 was predominantly detected in the T cells infiltrating sialadenitis from the onset of the disease, suggesting that CD4+ T cells bearing TCR V beta 8 play an essential role in recognizing unknown autopeptide in the autoimmune sialadenitis of MRL/lpr mice. Furthermore, Sjögren's syndrome-like autoimmune lesions were successfully transferred into severe combined immunodeficiency (SCID) mice, and these lesions were prevented by administration of anti-CD4, and anti-V beta 8 monoclonal antibodies. This article will review recent observations of these pathogenetic analyses of autoimmune sialadenitis as it occurs in MRL/lpr mice.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7952145     DOI: 10.1111/j.1440-1827.1994.tb01716.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  8 in total

Review 1.  Use of localised gene transfer to develop new treatment strategies for the salivary component of Sjögren's syndrome.

Authors:  M R Kok; B J Baum; P P Tak; S R Pillemer
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

Review 2.  Animal models of Sjögren's syndrome.

Authors:  Malin V Jonsson; Nicolas Delaleu; Roland Jonsson
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

3.  Lacrimal gland inflammation is responsible for ocular pathology in TGF-beta 1 null mice.

Authors:  N L McCartney-Francis; D E Mizel; M Frazier-Jessen; A B Kulkarni; J B McCarthy; S M Wahl
Journal:  Am J Pathol       Date:  1997-11       Impact factor: 4.307

Review 4.  Studying Sjögren's syndrome in mice: What is the best available model?

Authors:  Ghada Abughanam; Ola M Maria; Simon D Tran
Journal:  J Oral Biol Craniofac Res       Date:  2020-12-08

5.  Augmented levels of macrophage and Th1 cell-related cytokine mRNA in submandibular glands of MRL/lpr mice with autoimmune sialoadenitis.

Authors:  W Mustafa; J Zhu; G Deng; A Diab; H Link; L Frithiof; B Klinge
Journal:  Clin Exp Immunol       Date:  1998-06       Impact factor: 4.330

Review 6.  Assessing Autophagy in Mouse Models and Patients with Systemic Autoimmune Diseases.

Authors:  Fengjuan Wang; Baihui Li; Nicolas Schall; Maud Wilhelm; Sylviane Muller
Journal:  Cells       Date:  2017-06-28       Impact factor: 6.600

Review 7.  CD3+CD4-CD8- (Double-Negative) T Cells in Inflammation, Immune Disorders and Cancer.

Authors:  Zhiheng Wu; Yu Zheng; Jin Sheng; Yicheng Han; Yanyan Yang; Hongming Pan; Junlin Yao
Journal:  Front Immunol       Date:  2022-02-10       Impact factor: 7.561

8.  MyD88 signaling causes autoimmune sialadenitis through formation of high endothelial venules and upregulation of LTβ receptor-mediated signaling.

Authors:  Takeshi Into; Shumpei Niida; Ken-Ichiro Shibata
Journal:  Sci Rep       Date:  2018-09-24       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.